Today we published our response to the GMC consultation on 'Good practice in prescribing and managing medicines and devices'.
ABPI is fully supportive of the Bribery Act 2010. It is our policy to conduct all of our business in an honest and ethical manner. We take a zero-tolerance approach to bribery and corruption and are committed to acting professionally, fairly and with integrity in all our business dealings and...
Cogent, the Sector Skills Council for the science-based industries, has announced the Board appointment of pharmaceutical industry leader and former ABPI President Nigel Brooksby. Mr Brooksby will represent the life sciences industry on the Cogent Board, and is also the Chair of the Cogent Life...
The ABPI has responded to the Prime Minister's ‘Road to Brexit’ speech today at Mansion House.
On Wednesday 21 February, Health and Social Care Secretary Jeremy Hunt announced that Baroness Julia Cumberlege will lead a review into how the NHS responds to safety concerns raised by patients about medicines or medical devices.
The ABPI have responded today to an announcement by the Department of Health & Social Care who have published a 12 week consultation seeking views from interested parties on the recommendations in the Cost-Effectiveness Methodology for Immunisation Programmes and Procurement (CEMIPP).
As the MHRA publishes an update to pharmaceutical companies on preparing for Brexit, the ABPI reaffirms the importance of patient and public health in negotiations.
This morning, The Times published an investigation into the transfers of value received by healthcare professionals (HCPs) and healthcare organisations (HCOs) across Europe from the pharmaceutical industry.
This week, the Kings Fund published a new report into the cost of medicines looking at how much the health service spends in total on medicines; both generics and branded medicines.
This week, the House of Lords Science and Technology Committee published a report into the Life Sciences Industrial Strategy, asking: "Who's Driving the Bus?"
A report published by the Business, Energy and Indsutrial Strategy (BEIS) Strategy Committee, calls on the Government to secure a post-Brexit deal to protect patients and the UK's pharmaceutical industry.